Financial Review: ConforMIS (NASDAQ:CFMS) versus The Competition

ConforMIS (NASDAQ: CFMS) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare ConforMIS to similar businesses based on the strength of its earnings, dividends, analyst recommendations, risk, profitability, valuation and institutional ownership.

Valuation and Earnings

This table compares ConforMIS and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ConforMIS $79.90 million -$57.58 million -1.94
ConforMIS Competitors $1.67 billion $207.58 million 87.51

ConforMIS’s peers have higher revenue and earnings than ConforMIS. ConforMIS is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

ConforMIS has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, ConforMIS’s peers have a beta of 0.47, suggesting that their average share price is 53% less volatile than the S&P 500.

Insider and Institutional Ownership

36.1% of ConforMIS shares are held by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 9.6% of ConforMIS shares are held by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares ConforMIS and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ConforMIS -72.70% -76.88% -51.42%
ConforMIS Competitors -101.23% -92.70% -30.32%

Analyst Ratings

This is a summary of current recommendations for ConforMIS and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ConforMIS 0 3 2 0 2.40
ConforMIS Competitors 111 728 1026 10 2.50

ConforMIS currently has a consensus target price of $6.13, indicating a potential upside of 135.58%. As a group, “Medical Devices & Implants” companies have a potential upside of 35.72%. Given ConforMIS’s higher possible upside, research analysts clearly believe ConforMIS is more favorable than its peers.

Summary

ConforMIS peers beat ConforMIS on 8 of the 12 factors compared.

ConforMIS Company Profile

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply